Study to Evaluate the Efficacy and Safety of Andecaliximab Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma

NCT02864381 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

144

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastric Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG: Andecaliximab
DRUG: Nivolumab

Sponsor

Gilead Sciences